Pcv40 - Budget Impact Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.587
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcv76 - Cost-Effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2011English

Rivaroxaban for Secondary Prophylaxis of Atherothrombosis Complications in Patients With Recent Acute Coronary Syndrome

Kardiologiya
Cardiovascular MedicineCardiology
2017English

Evidence of Poor Adherence to Secondary Prevention After Acute Coronary Syndromes: Possible Remedies Through the Application of New Technologies

Open Heart
Cardiovascular MedicineCardiology
2015English

Acute Coronary Syndromes

British Medical Journal
Medicine
2015English

Acute Coronary Syndromes

2018English

Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, but Where Are We Headed?

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2019English

Acute Coronary Syndromes

JAMA - Journal of the American Medical Association
Medicine
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy